US2016272729A1PendingUtilityA1

Method of treating a pathological syndrome and a pharmaceutical agent

Assignee: EPSHTEIN OLEG ILIICHPriority: Jun 20, 2000Filed: May 31, 2016Published: Sep 22, 2016
Est. expiryJun 20, 2020(expired)· nominal 20-yr term from priority
A61P 9/10A61P 3/04A61P 37/00A61P 9/00A61P 43/00C07K 16/24A61K 31/277A61K 41/0004A61K 2039/505A61P 29/00C07K 16/26C07K 16/243C07K 16/44C07K 16/00C07K 2317/73A61P 3/10A61P 25/30A61P 31/00C07K 16/248A61P 25/32A61P 25/18C07K 16/22A61P 25/34C07K 16/2806C07K 16/249C07K 16/28C07K 16/245C07K 2317/77C07K 16/241A61P 25/24A61K 2039/545A61K 39/39583C07K 16/40C07K 16/246A61P 25/36A61P 25/28C07K 2317/75A61P 31/12A61P 25/16
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too.

Claims

exact text as granted — not AI-modified
1 .- 16 . (canceled) 
     
     
         17 . A method of administering to a subject suffering from acute or chronic pain a homeopathically activated form of an antibody to a pharmaceutically agent, wherein the molecular form of said pharmaceutical agent is involved in the regulation of pain. 
     
     
         18 .- 22 . (canceled) 
     
     
         23 . The method of  claim 17  wherein the pharmaceutically agent is selected from morphine, phentanyl, dihydroergotamine, sumatriptane, indomethacine, ibuprofen, aspirin, calcitonin, hydrocortisone, and ranitidine. 
     
     
         24 .- 32 . (canceled)

Join the waitlist — get patent alerts

Track US2016272729A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.